1. Use of a vibrating mesh nebulizer for allergen challenge
- Author
-
Donald W. Cockcroft, Beth E. Davis, Christianne M. Blais, Louis-Philippe Boulet, Marie-Éve Boulay, Hélène Villeneuve, Gail M. Gauvreau, Paul M. O’Byrne, Karen J. Howie, and Caitlin D. Obminski
- Subjects
Allergen inhalation test ,Methacholine inhalation test ,Skin test endpoint ,Jet nebulizer (Wright®) ,Vibrating mesh nebulizer (Solo®) ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Background Allergen inhalation tests are a valuable research tool. The allergen dose producing an early asthmatic response (EAR) can be predicted from methacholine responsiveness and allergen skin test endpoint (STE). The Wright® jet nebulizer, which is both inefficient and increasingly difficult to obtain, has been used historically. We assessed the Solo® vibrating mesh nebulizer as an alternative for allergen and methacholine challenges. Methods Eighteen mild atopic asthmatics completed the study. Doubling concentration allergen prick skin tests were performed to determine the STE in allergen units/mL. The Wright® protocol was used to measure the methacholine provocation dose causing a 20% forced expired volume in one second (FEV1) fall (PD20) (μg) and the allergen PD20 (units). The Solo® protocol (0.5 mL nebulized to completion, tidal breathing inhalation) was used to determine both methacholine PD20 and allergen PD20. The nebulizer order was randomized and separated by ≥ 2 weeks. Results All data were log transformed. The allergen PD20, predicted from the methacholine PD20 and the STE, was within 2 doubling doses of the PD20 measured with the Wright® and 2.64 doubling doses of that measured with Solo®. The Wright® allergen PD20 correlated with the Wright® methacholine PD20 (r = 0.74) and the STE (r = 0.78) and more strongly with the product of the two (Wright® methacholine PD20 × STE, r = 0.91, p
- Published
- 2019
- Full Text
- View/download PDF